IP Library Granted Patent US 12678534
Granted Patent B2
US 12678534 · App. 18/311,205 · Granted Jul 14, 2026

Submucosal lifting and hemostatic sealing hydrogel

Inventors: Philip David Dorgan (Cork, IE); Edward Joseph Devlin (Cork, IE); Conor O'Sullivan (Cork, IE); John Murphy (Cork, IE); Mark Looney (Cork, IE); Paul O'Farrell (Cork, IE)
Assignee: Boston Scientific Scimed, Inc.
A61L24/08A61L24/0015A61L24/0031A61L2300/418A61L2400/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12678534
App. No.
18/311,205
Granted
Jul 14, 2026
Kind
B2
Abstract

In some aspects, the present disclosure pertains to injectable polysaccharide-based hydrogels that comprises an anionic polysaccharide, a cationic crosslinking agent and a hemostatic agent. In some aspects, the present disclosure pertains to medical devices containing such injectable polysaccharide-based hydrogels, to kits that contain such injectable polysaccharide-based hydrogels, and to methods of using such injectable polysaccharide-based hydrogels.

Claims (20)

1 . An injectable polysaccharide-based hydrogel that comprises an anionic polysaccharide, a cationic crosslinking agent and a hemostatic agent.

2 . The injectable polysaccharide-based hydrogel of claim 1 , wherein the anionic polysaccharide is provided at a concentration ranging from about 0.05% to about 1.0%, with respect to the total weight of the injectable polysaccharide-based hydrogel.

3 . The injectable polysaccharide-based hydrogel of claim 1 , wherein the hemostatic agent is selected from an organic polymeric hemostatic agent, a small molecule organic hemostatic agent, a large molecule organic hemostatic agent, and an inorganic hemostatic agent.

4 . The injectable polysaccharide-based hydrogel of claim 3 , wherein the hemostatic agent is selected from chitosan, hydroxyapatite or tranexamic acid.

5 . The injectable polysaccharide-based hydrogel of claim 1 , wherein the hemostatic agent is in particulate form and is less than 50000 nm in average particle size.

6 . The injectable polysaccharide-based hydrogel of claim 5 , wherein the hemostatic agent comprises a core comprising a chitosan salt and a shell comprising a polyanionic crosslinking agent.

7 . The injectable polysaccharide-based hydrogel of claim 1 , wherein the hemostatic agent is provided at a concentration ranging from about 5% to about 50%, with respect to the total weight of the injectable polysaccharide-based hydrogel.

8 . A method of separating and elevating an upper mucosal layer from a lower layer, the method comprising injecting the injectable polysaccharide-based hydrogel of claim 1 through a needle into a target treatment site between the upper mucosal layer and the lower layer.

9 . The method of claim 8 , wherein the method is performed as part of an endoscopic mucosal resection procedure or an endoscopic submucosal dissection procedure.

10 . The method of claim 8 , wherein the medical device further comprises a flexible tube that couples the syringe barrel to the needle and wherein the injectable polysaccharide-based hydrogel is injected from the syringe barrel, through the flexible tube, through the needle and into the target site.

11 . The injectable polysaccharide-based hydrogel of claim 1 , wherein the anionic polysaccharide contains a repeating unit of glucuronic acid.

12 . The injectable polysaccharide-based hydrogel of claim 1 , wherein the anionic polysaccharide comprises gellan gum.

13 . The injectable polysaccharide-based hydrogel of claim 1 , wherein the cationic crosslinking agent comprises a salt comprising a divalent metal cation.

14 . The injectable polysaccharide-based hydrogel of claim 1 , wherein the cationic crosslinking agent is provided at a concentration ranging from about 0.01%% to about 0.25%, with respect to the total weight of the injectable polysaccharide-based hydrogel.

15 . A medical device comprising a reservoir that contains the injectable polysaccharide-based hydrogel of claim 1 .

16 . The medical device of claim 15 , wherein the reservoir is a syringe barrel.

17 . The medical device of claim 16 , wherein the medical device further comprises a needle through which the injectable polysaccharide-based hydrogel is injected.

18 . Use of the medical device of claim 17 in a medical procedure in which an upper mucosal layer is elevated from a lower layer.

19 . A kit comprising the medical device of claim 17 and one or more items selected from (a) an endoscopic injection needle, (b) tissue resection device, (c) a tissue retrieval device, and (d) an endoscope, within a suitable packaging material.

20 . The method of claim 8 , comprising removing tissue raised by the injectable polysaccharide-based hydrogel.